Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288578 | 0.84 | ELANE (0.30) | ELANE | |
| SCHEMBL31597450 | 0.83 | — | — | |
| SCHEMBL8404403 | 0.83 | ELANE (0.33) | ELANE | |
| SCHEMBL13184246 | 0.76 | ALDH1A1 (0.35) | ELANE | |
| SCHEMBL27050828 | 0.76 | SLC6A2 (0.39) | — | |
| SCHEMBL24819184 | 0.76 | NOS3 (0.33) | ELANE | |
| SCHEMBL15919048 | 0.73 | ELANE (0.34) | ELANE | |
| SCHEMBL23839498 | 0.71 | MTNR1A (0.34) | — | |
| SCHEMBL23870219 | 0.68 | HTR2A (0.34) | — | |
| SCHEMBL24819186 | 0.68 | NOS3 (0.33) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9040531-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | PRISM BIOLAB CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2427451-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BioLab Corporation (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2346871-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BioLab Corporation (JP) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010128685-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010044485-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | F2RL1 3569/4885ELANE 886/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | F2RL1 3569/4885ELANE 886/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | F2RL1 3569/4885ELANE 886/4885 |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | COL1A1, HDGF, HCCS | F2RL1 3918/4885ELANE 796/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | F2RL1 3569/4885ELANE 886/4885 |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | F2RL1 3836/4885ELANE 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.